1. Acknowledgement to Referees

   Acknowledgement to Referees 01 December 2015 Pages: 363 - 364

2. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders

   • Gustavo Grampp
   • Sundar Ramanan

   Current Opinion Open access 18 November 2015 Pages: 365 - 372

   

3. Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers

   • Kevin Klein
   • Marie L. De Bruin
   • Pieter Stolk

   Short Communication Open access 30 November 2015 Pages: 373 - 379

4. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade^®) in Healthy Subjects

   • Donghoon Shin
   • Youngdoe Kim
   • Rainard Fuhr

   Original Research Article Open access 17 November 2015 Pages: 381 - 388

   

5. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden

   • Jenny M. Norlin
   • Katarina Steen Carlsson
   • Marcus Schmitt-Egenolf

   Original Research Article 15 December 2015 Pages: 389 - 398

   

6. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease

   • Katherine A. Lyseng-Williamson

   Adis Drug Evaluation 22 September 2015 Pages: 399 - 406

   

7. Dulaglutide: A Review in Type 2 Diabetes

   • Celeste B. Burness
   • Lesley J. Scott

   Adis Drug Evaluation 30 September 2015 Pages: 407 - 418